Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price traded down 1.9% during mid-day trading on Monday . The company traded as low as $56.22 and last traded at $56.91. Approximately 275,330 shares traded hands during trading, an increase of 45% from the average session volume of 189,291 shares. The stock had previously closed at $58.00.
Gemini Therapeutics Stock Down 1.9%
The company has a fifty day simple moving average of $50.05 and a 200 day simple moving average of $51.61. The firm has a market capitalization of $2.47 billion, a P/E ratio of -56.91 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- These 3 Undervalued Stocks Could Surge as Value Rotation Nears
- Quiet Period Expirations Explained
- Tilray Shares Blazing: What’s Behind the 55% Rally This Month?
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
